As you know SYNCROSOME is a Preclinical Drug Evaluation Company specialised in human health.
Since 2000, Syncrosome is mainly focused on in vivo efficacy studies dedicated to discovery and preclinical stage with more than 25 animal models, to provide you the right data to make the right decision.
We offer our services and our expertise in the development of Central Nervous System, Respiratory, Cardiovascular, Gastroenterology, Inflammation and Metabolic Disorder drugs to Big Pharma, Midsiz...
Chronic Obstructive Pulmonary Diseases (COPD) is a long-term lung disease often caused by smoking. One of the most common symptoms of COPD are persistent cough, shortness of breath, and excess mucus.
In 2013 more than 330 million people suffer from COPD. By 2030, the World Health Organisation estimates that COPD will become the third leading cause of death.
Unfortunately, while many medications are available to treat COPD, none of them has demonstrated effectiveness in halting the progress...
Syncrosome is a Preclinical Drug Evaluation Company specialised in human and animal health in vivo pharmacological studies. Syncrosome has the professional expertise to complete studies independently or to work in parallel with in-house research teams, after preliminary in vitro screenings - www.syncrosome.com